The highly heterogeneous nature of diseases such as cancer means that a ‘one drug for all’ approach has limited capacity to be effective. To tailor therapies to the individual patient, a multi-disciplined approach is required which takes into consideration both the genetic drivers of disease and functional response.

Watch this insightful panel discussion where leading scientists from Nantes Université, Sampled, Misvik Biology, and Exscientia share their experience of tackling key hurdles in precision medicine and predict the challenges that lie ahead.

Key discussion areas include:

• Approaches to monitor treatment efficacy
• Guiding treatment decisions with ex vivo drug screening
• Standardization between centers

Don't miss this opportunity to hear an exciting, active conversation from leading researchers. Revvity is the sole sponsor of this panel discussion.

The opinions expressed in the panel are those of the panelists only, and do not purport to reflect the opinions or views of Revvity or its employees.

For research use only. Not for use in diagnostic procedures.